{"id":34623,"date":"2026-03-02T17:54:00","date_gmt":"2026-03-02T12:24:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34623"},"modified":"2026-03-25T13:22:14","modified_gmt":"2026-03-25T07:52:14","slug":"bysanti-approval-for-antipsychotic-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment","title":{"rendered":"BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market"},"content":{"rendered":"\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>The U.S. FDA approved Vanda Pharmaceuticals\u2019 BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.<\/em><\/li>\n\n\n\n<li><em>BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone).<\/em><\/li>\n\n\n\n<li><em>Vanda\u2019s stock surged nearly 40% after BYSANTI\u2019s approval, reflecting renewed investor confidence.<\/em><\/li>\n\n\n\n<li><em>BYSANTI\u2019s launch is expected by Q3 2026, contributing to portfolio diversification and revenue growth.<\/em><\/li>\n<\/ul>\n\n\n\n<p><strong>Vanda Pharmaceuticals\u2019 atypical antipsychotic BYSANTI (milsaperidone)<\/strong> has won FDA approval for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\">treatment of schizophrenia<\/a> and for manic or mixed episodes associated with bipolar I disorder, positioning the company back on offense in central nervous system (CNS) therapeutics after a high\u2011profile setback with its jet lag drug. Grounded in the pharmacology and extensive clinical heritage of Vanda\u2019s existing antipsychotic <strong>FANAPT (iloperidone)<\/strong>, BYSANTI is designed to offer prescribers a familiar mechanism in a new formulation that can be deployed from the front line of care.<\/p>\n\n\n\n<p>The FDA has cleared BYSANTI as a frontline atypical antipsychotic for two major psychiatric indications: schizophrenia and manic or mixed episodes in <a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\">patients with bipolar I disorder<\/a>. These are overlapping but clinically distinct populations in which effective management of psychosis, mood instability, and functional impairment remains a major unmet need despite the availability of multiple antipsychotic classes.<\/p>\n\n\n\n<p><em>According to Sadaf, Manager of Forecasting and Analytics at DelveInsight, BYSANTI\u2019s approval allows clinicians to consider it early in the treatment algorithm, rather than relegating it to a niche or refractory-disease role. This positioning is important commercially and clinically because front\u2011line status shapes formulary negotiations, guideline inclusion, and real\u2011world prescribing patterns from the outset of launch.<\/em><\/p>\n\n\n\n<p>Scientifically, BYSANTI is notable because it is based on iloperidone, the active moiety that forms the core of Vanda\u2019s existing antipsychotic FANAPT. Milsaperidone, the active ingredient in BYSANTI, is an active metabolite of a compound that underlies FANAPT; once taken orally, BYSANTI rapidly interconverts to iloperidone in the body.<\/p>\n\n\n\n<p>Iloperidone\u2019s pharmacology is characterized by antagonism of dopamine D2 receptors, <a href=\"https:\/\/www.delveinsight.com\/report-store\/5-ht2a-agonist-pipeline-insight\">serotonin 5\u2011HT2A receptors<\/a>, and alpha1\u2011adrenergic receptors, a receptor\u2011binding profile that is typical of many second\u2011generation, or \u201catypical,\u201d antipsychotics. This multi\u2011receptor targeting underpins both antipsychotic efficacy and the nuanced side\u2011effect profiles that differentiate agents within the class.<\/p>\n\n\n\n<p>By building BYSANTI around an already well\u2011understood pharmacologic scaffold, Vanda is not trying to reinvent antipsychotic treatment from scratch; instead, it is repackaging a known entity in a way that may offer practical and lifecycle advantages while preserving a familiar mechanism of action for prescribers.<\/p>\n\n\n\n<p>Vanda\u2019s development strategy for BYSANTI relied heavily on demonstrating its pharmacokinetic and clinical comparability to Fanapt. The company has shown that BYSANTI is bioequivalent to FANAPT, with pharmacokinetic profiles that follow similar trajectories over time when the drugs are administered. Such bioequivalence data suggest that systemic exposure to the active moiety is similar between the two products, supporting the inference that efficacy and safety should align closely.<\/p>\n\n\n\n<p>Beyond direct bioequivalence trials, Vanda anchored its regulatory package in what it describes as the \u201cwell\u2011established knowledge of efficacy and safety\u201d of FANAPT, encompassing more than 100,000 patient\u2011years of clinical and real\u2011world experience. This long\u2011term, large\u2011scale exposure record is critical in psychiatry, where chronic treatment is the rule rather than the exception and where rare but serious side effects must be well characterized.<\/p>\n\n\n\n<p>In public statements around the approval, Vanda has emphasized that this heritage allows BYSANTI to be presented as a \u201creliable new treatment grounded in extensive clinical heritage,\u201d highlighting continuity rather than novelty as a core part of its value proposition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"363\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-1024x363.webp\" alt=\"BYSANTI-Development-Timeline\" class=\"wp-image-34628\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-1024x363.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-300x106.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-150x53.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-768x272.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline-1536x544.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/BYSANTI-Development-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Schizophrenia and bipolar I disorder are both chronic, relapsing illnesses in which relapse prevention, symptom stabilization, and functional recovery require sustained pharmacologic management. An atypical antipsychotic with a known receptor profile and a large pre\u2011existing dataset can be attractive to clinicians who must often balance efficacy, tolerability, and patient preference over the long term.<\/p>\n\n\n\n<p>BYSANTI\u2019s shared indication set with FANAPT, schizophrenia, and manic or mixed episodes in bipolar disorder, means that many prescribers will conceptualize it within an already familiar clinical space. In practice, this can facilitate more rapid adoption if physicians perceive BYSANTI as offering comparable benefits with potential advantages in formulation, titration, or commercial access, even without a fundamentally new mechanism.<\/p>\n\n\n\n<p>The timing of BYSANTI\u2019s approval is strategically meaningful for Vanda. Earlier in the year, the FDA rejected the company\u2019s attempt to expand its sedative <strong>Hetlioz <\/strong>into jet lag disorder, arguing that the submitted data did not adequately demonstrate efficacy in that setting. Vanda publicly disputed that conclusion, pointing out that the experimental models it used are widely accepted in circadian rhythm research as surrogates for eastward jet lag\u2013related circadian misalignment.<\/p>\n\n\n\n<p>That rejection was not an isolated event but part of a protracted dispute between the company and the agency over the jet lag indication. Hetlioz was first rejected in 2019, prompting Vanda to appeal and, after limited agency engagement, to sue the FDA in 2022. A federal judge in March 2024 ordered the agency either to grant Vanda a hearing or resolve the application; the FDA chose to resolve it, which led to another appeal by Vanda that it subsequently won in August 2025. Against that backdrop, a clean, positive decision on BYSANTI provides reputational and strategic relief, signaling that Vanda can still navigate complex CNS approvals despite past regulatory friction.<\/p>\n\n\n\n<p>BYSANTI\u2019s green light also comes on the heels of another key CNS win for Vanda: the <a href=\"https:\/\/www.delveinsight.com\/report-store\/nausea-and-vomiting-induced-by-motion-sickness-market\">FDA\u2019s approval of NEREUS for motion sickness<\/a> late last year, which was described as the first approval for this indication in more than four decades. That milestone, combined with BYSANTI and the ongoing commercial presence of Fanapt and Hetlioz in other indications, underscores Vanda\u2019s ambition to be a diversified CNS company rather than a single\u2011asset player.<\/p>\n\n\n\n<p>In this context, BYSANTI does more than add one more SKU to the portfolio. Paired with Nereus, it demonstrates that Vanda can deliver both incremental and category\u2011redefining assets across different parts of the CNS spectrum, from psychotic disorders and mood instability to acute vestibular symptoms like motion sickness.<\/p>\n\n\n\n<p>Vanda has indicated that it expects to make BYSANTI available by the third quarter of the year following approval. The market responded positively to the announcement, with Vanda\u2019s share price climbing nearly 40% between the close of trading on the day of the approval and the following Monday\u2019s pre\u2011market session. Such a move reflects investor expectations that BYSANTI will contribute meaningfully to revenue and help de\u2011risk the company in light of its contentious regulatory history with Hetlioz.<\/p>\n\n\n\n<p><em>Sadaf further said that BYSANTI enters a crowded atypical antipsychotic landscape, but does so with the advantage of a thoroughly characterized active moiety and a regulatory label that supports frontline use in two of the most burdensome psychiatric conditions. Clinicians who are already comfortable with FANAPT\u2019s efficacy and tolerability profile may be particularly inclined to consider BYSANTI for appropriate patients if it offers practical advantages in dosing or access, even absent a radical mechanistic shift.<\/em><\/p>\n\n\n\n<p>Taken together, BYSANTI\u2019s approval, NEREUS\u2019 recent success in motion sickness, and the long\u2011running but still active saga around Hetlioz\u2019s jet lag application paint a picture of a company at a strategic inflection point. BYSANTI is not a moon\u2011shot radical innovation; instead, it is a carefully structured, evidence\u2011anchored evolution of a known drug, designed to consolidate Vanda\u2019s position in the <a href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\">antipsychotic market<\/a> while signalling to regulators, investors, and clinicians that the company can execute on complex CNS programs.<\/p>\n\n\n\n<p>In an era when psychiatric drug development remains scientifically challenging and commercially risky, a product like BYSANTI, rooted in deep clinical heritage but packaged as a new, frontline\u2011ready option, may represent a pragmatic model for innovation: one that emphasizes reliability, regulatory tractability, and portfolio cohesion as much as it does mechanistic novelty.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-1024x194.png\" alt=\"Schizophrenia Market Outlook\" class=\"wp-image-29826\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/30162735\/Schizophrenia-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Vanda Pharmaceuticals\u2019 atypical antipsychotic BYSANTI (milsaperidone) has won FDA approval for the treatment of schizophrenia and for manic or mixed episodes associated with bipolar I disorder, positioning the company back on offense in central nervous system (CNS) therapeutics after a high\u2011profile setback with its jet lag drug. Grounded in the pharmacology and extensive clinical [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34625,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22910,22034,22909,22031,21333,1519,22298],"industry":[],"therapeutic_areas":[],"class_list":["post-34623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-antipsychotic","tag-bipolar-i-disorder","tag-bysanti","tag-fanapt","tag-motion-sickness","tag-schizophrenia","tag-schizophrenia-drugs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vanda\u2019s BYSANTI: A New Era in Antipsychotic Treatment<\/title>\n<meta name=\"description\" content=\"FDA approved Vanda\u2019s BYSANTI for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanda\u2019s BYSANTI: A New Era in Antipsychotic Treatment\" \/>\n<meta property=\"og:description\" content=\"FDA approved Vanda\u2019s BYSANTI for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T12:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T07:52:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vanda\u2019s BYSANTI: A New Era in Antipsychotic Treatment","description":"FDA approved Vanda\u2019s BYSANTI for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment","og_locale":"en_US","og_type":"article","og_title":"Vanda\u2019s BYSANTI: A New Era in Antipsychotic Treatment","og_description":"FDA approved Vanda\u2019s BYSANTI for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.","og_url":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-02T12:24:00+00:00","article_modified_time":"2026-03-25T07:52:14+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment","url":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment","name":"Vanda\u2019s BYSANTI: A New Era in Antipsychotic Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment.webp","datePublished":"2026-03-02T12:24:00+00:00","dateModified":"2026-03-25T07:52:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA approved Vanda\u2019s BYSANTI for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/bysanti-approval-for-antipsychotic-treatment#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment.webp","width":466,"height":284,"caption":"bysanti-approval-for-antipsychotic-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/bysanti-approval-for-antipsychotic-treatment-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antipsychotic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">bipolar I disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BYSANTI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fanapt<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Motion Sickness<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Schizophrenia Drugs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antipsychotic<\/span>","<span class=\"advgb-post-tax-term\">bipolar I disorder<\/span>","<span class=\"advgb-post-tax-term\">BYSANTI<\/span>","<span class=\"advgb-post-tax-term\">Fanapt<\/span>","<span class=\"advgb-post-tax-term\">Motion Sickness<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia Drugs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 3 weeks ago"},"absolute_dates":{"created":"Posted on Mar 2, 2026","modified":"Updated on Mar 25, 2026"},"absolute_dates_time":{"created":"Posted on Mar 2, 2026 5:54 pm","modified":"Updated on Mar 25, 2026 1:22 pm"},"featured_img_caption":"bysanti-approval-for-antipsychotic-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34623"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34623\/revisions"}],"predecessor-version":[{"id":34856,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34623\/revisions\/34856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34625"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34623"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34623"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}